{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:15:59Z","timestamp":1793042159631,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-024-10846-w","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T16:02:06Z","timestamp":1719849726000},"page":"7622-7631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diagnostic performance of CT\/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease"],"prefix":"10.1007","volume":"34","author":[{"given":"Jennie","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Shon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Kamaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2408-3763","authenticated-orcid":false,"given":"Justin R.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"10846_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723\u2013750","journal-title":"Hepatology"},{"key":"10846_CR2","unstructured":"American College of Radiology Committee on LI-RADS\u00ae (2023) Available at https:\/\/www.acr.org\/Clinical-Resources\/Reporting-and-Data-Systems\/LI-RADS. Accessed Jul 15"},{"key":"10846_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","volume":"17","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Stepanova M, Ong JP et al (2019) Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 17:748\u2013755.e3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10846_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7:851\u2013861","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10846_CR5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ et al (2023) Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol 29:S32\u2013S42","journal-title":"Clin Mol Hepatol"},{"key":"10846_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3350\/cmh.2022.0239","volume":"28","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Zou B et al (2022) Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol 28:841\u2013850","journal-title":"Clin Mol Hepatol"},{"key":"10846_CR7","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.3390\/ijms20205037","volume":"20","author":"DH Fernando","year":"2019","unstructured":"Fernando DH, Forbes JM, Angus PW, Herath CB (2019) Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products. Int J Mol Sci 20:5037","journal-title":"Int J Mol Sci"},{"key":"10846_CR8","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.30946","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba R, Adams LA (2019) The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70:1885\u20131888","journal-title":"Hepatology"},{"key":"10846_CR9","first-page":"32294","volume":"S0168-8278","author":"GA Kim","year":"2017","unstructured":"Kim GA, Lee HC, Choe J et al (2017) Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol S0168-8278:32294\u201332298","journal-title":"J Hepatol"},{"key":"10846_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M (2019) From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 16:411\u2013428","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10846_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2214\/AJR.20.24272","volume":"216","author":"RM Marks","year":"2021","unstructured":"Marks RM, Masch WR, Chernyak V (2021) LI-RADS: past, present, and future, from the AJR Special Series on Radiology Reporting and Data Systems. AJR Am J Roentgenol 216:295\u2013304","journal-title":"AJR Am J Roentgenol"},{"key":"10846_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hep.28368","volume":"63","author":"F Piscaglia","year":"2016","unstructured":"Piscaglia F, Svegliati-Baroni G, Barchetti A et al (2016) Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 63:827\u2013838","journal-title":"Hepatology"},{"key":"10846_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2024) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 29:101133. https:\/\/doi.org\/10.1016\/j.aohep.2023.101133","journal-title":"Ann Hepato"},{"key":"10846_CR14","unstructured":"LI-RADS Lexicon Table (2023) Available at https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/LI-RADS\/LIRADS-Lexicon-Table.pdf. Accessed 15 Jul 2023"},{"key":"10846_CR15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220646","volume":"307","author":"S Lee","year":"2023","unstructured":"Lee S, Kim YY, Shin J et al (2023) Percentages of hepatocellular carcinoma in LI-RADS categories with CT and MRI: a systematic review and meta-analysis. Radiology 307:e220646","journal-title":"Radiology"},{"key":"10846_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1053\/j.gastro.2016.11.042","volume":"152","author":"JC Nault","year":"2017","unstructured":"Nault JC, Couchy G, Balabaud C et al (2017) Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 152:880\u2013894.e6","journal-title":"Gastroenterology"},{"key":"10846_CR17","doi-asserted-by":"crossref","unstructured":"Tse JR, Felker ER, Cao JJ et al (2023) Hepatocellular adenoma subtypes based on 2017 classification system: exploratory study of gadoxetate disodium-enhanced mri features with proposal of a diagnostic algorithm. AJR Am J Roentgenol 220:539\u2013550","DOI":"10.2214\/AJR.22.28233"},{"key":"10846_CR18","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220134","volume":"43","author":"JR Tse","year":"2023","unstructured":"Tse JR, Felker ER, Naini BV et al (2023) Hepatocellular adenomas: molecular basis and multimodality imaging update. Radiographics 43:e220134","journal-title":"Radiographics"},{"key":"10846_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681\u2013693","journal-title":"J Hepatol"},{"key":"10846_CR20","doi-asserted-by":"publisher","first-page":"7760","DOI":"10.1007\/s00330-021-07897-8","volume":"31","author":"JA Hwang","year":"2021","unstructured":"Hwang JA, Min JH, Kang TW et al (2021) Assessment of factors affecting washout appearance of hepatocellular carcinoma on CT. Eur Radiol 31:7760\u20137770","journal-title":"Eur Radiol"},{"key":"10846_CR21","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1007\/s00330-020-07438-9","volume":"31","author":"JH Min","year":"2021","unstructured":"Min JH, Kang TW, Kim YY et al (2021) Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI. Eur Radiol 31:3315\u20133325","journal-title":"Eur Radiol"},{"key":"10846_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","volume":"75","author":"R Pinyol","year":"2021","unstructured":"Pinyol R, Torrecilla S, Wang H et al (2021) Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 75:865\u2013878","journal-title":"J Hepatol"},{"key":"10846_CR23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jhep.2020.01.019","volume":"72","author":"M M\u00fcller","year":"2020","unstructured":"M\u00fcller M, Bird TG, Nault JC (2020) The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol 72:990\u20131002","journal-title":"J Hepatol"},{"key":"10846_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R et al (2021) NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592:450\u2013456","journal-title":"Nature"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10846-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-10846-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-10846-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T23:03:55Z","timestamp":1731452635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-10846-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10846"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-10846-w","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Justin R. Tse.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"Justin R. Tse receives grant support from GE Healthcare and Bayer Healthcare and is a consultant for Intuitive Surgical, Inc. and AbSolutions Med, Inc. Luke Yoon is a consultant for Intuitive Surgical, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval (Stanford University) was obtained. No animals were included in this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None study subjects or cohorts have been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}